Intravenous Dexmedetomidine as a Perioperative Autonomic-Immune Neuromodulator
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 90 years old?
Source: NCT07743853, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Poznan University of Medical Sciences
- Trial code
- NCT07743853
- Record updated
- 5 November 2026
- Original description
Surgical trauma induces activation of the sympathetic nervous system and triggers a systemic inflammatory response that may adversely affect postoperative recovery. Dexmedetomidine, a highly selective α2-adrenoceptor agonist, has been proposed as a pharmacological neuromodulatory strategy capable of attenuating sympathetic activation and modulating neuroimmune interactions during the perioperative period. However, the extent to which intravenous dexmedetomidine influences perioperative inflammatory biomarkers and clinical recovery in patients undergoing total hip arthroplasty under regional anesthesia remains unclear.Read full original descriptionShow less
Intravenous Dexmedetomidine as a Perioperative Autonomic-Immune Neuromodulator in Total Hip Arthroplasty: a Randomized Double-Blind Trial
Surgical trauma induces activation of the sympathetic nervous system and triggers a systemic inflammatory response that may adversely affect postoperative recovery. Dexmedetomidine, a highly selective α2-adrenoceptor agonist, has been proposed as a pharmacological neuromodulatory strategy capable of attenuating sympathetic activation and modulating neuroimmune interactions during the perioperative period. However, the extent to which intravenous dexmedetomidine influences perioperative inflammatory biomarkers and clinical recovery in patients undergoing total hip arthroplasty under regional anesthesia remains unclear.
This prospective, randomized, double-blind, placebo-controlled trial aims to evaluate the effects of two doses of intravenous dexmedetomidine administered during spinal anesthesia combined with ultrasound-guided pericapsular nerve group (PENG) block on autonomic regulation, systemic inflammatory response, postoperative pain, opioid consumption, and quality of recovery following elective primary total hip arthroplasty.
Inclusion: Adults aged 50-90 years; Scheduled for elective primary total hip arthroplasty due to primary hip osteoarthritis; American Society of Anesthesiologists (ASA) physical status I-III; Planned spinal anesthesia combined with ultrasound-guided Pericapsular Nerve Group (PENG) block; Ability to understand the study procedures and provide written informed consent.
Exclusion: Chronic opioid therapy (>3 months before surgery); Chronic treatment with α2-adrenergic agonists; Participation in another interventional clinical trial within the previous 30 days; Allergy or hypersensitivity to dexmedetomidine, ropivacaine, bupivacaine, or study medications; Resting heart rate <50 beats/min; Severe hepatic impairment (Child-Pugh class C); Severe renal failure requiring dialysis; Cognitive impairment or inability to complete postoperative questionnaires; Infection at the injection site; Refusal to participate or inability to provide written informed consent; Contraindications to spinal anesthesia; Contraindications to PENG block; Second- or third-degree atrioventricular block without a permanent pacemaker; Coagulopathy or ongoing anticoagulation precluding neuraxial anesthesia according to current guidelines; Revision total hip arthroplasty; Simultaneous bilateral total hip arthroplasty.